# Carboplatin-Paclitaxel ± Bevacizumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer

> **NCT01770171** · PHASE2 · UNKNOWN · sponsor: **Catholic University of the Sacred Heart** · enrollment: 108 (estimated)

## Conditions studied

- Stage III-IV or Recurrent Endometrial Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles

## Key facts

- **NCT ID:** NCT01770171
- **Lead sponsor:** Catholic University of the Sacred Heart
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-04
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2013-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01770171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01770171, "Carboplatin-Paclitaxel ± Bevacizumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01770171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*